Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 32 results.
User Information
Export Records
  1. 1.   Plasma Stability and Plasma Metabolite Concentration-Time Profiles of Oligo(Lactic Acid)8-Paclitaxel Prodrug Loaded Polymeric Micelles
  2. Repp, Lauren; Skoczen,Sarah; Rasoulianboroujeni, Morteza; Stern,Steve; Kwon, Glen S
  3. The AAPS Journal. 2023, Apr 11; 25(3): 39.
  1. 2.   Bioequivalence assessment of high-capacity polymeric micelle nanoformulation of paclitaxel and Abraxane (R) in rodent and non-human primate models using a stable isotope tracer assay
  2. Hwang, Duhyeong; Vinod, Natasha; Skoczen,Sarah; Ramsey, Jacob D.; Snapp,Kelsie; Montgomery, Stephanie A.; Wang, Mengzhe; Lim, Chaemin; Frank, Jonathan E.; Sokolsky-Papkov, Marina; Li, Zibo; Yuan, Hong; Kabanov, Alexander; Stern,Steve
  3. Biomaterials . 2021, Nov; 278
  1. 3.   The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
  2. Higuchi, Takashi; Kawaguchi, Kei; Miyake, Kentaro; Oshiro, Hiromichi; Zhang, Zhiying; Razmjooei, Sahar; Wangsiricharoen, Sintawat; Igarashi, Kentaro; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Nelson, Scott D; Dry, Sarah M; Li, Yunfeng; Chawla, Sant P; Eilber, Frederick C; Singh, Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M
  3. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2019, Jan 04; 111: 835-840.
  1. 4.   Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab
  2. Gardner, E. R.; Kelly, M.; Springman, E.; Lee, K. J.; Li, H. Q.; Moore, W.; Figg, W. D.
  3. Investigational New Drugs. 2012, Feb; 30(1): 90-97.
  1. 5.   Human Dosimetry and Preliminary Tumor Distribution of (18)F-Fluoropaclitaxel in Healthy Volunteers and Newly Diagnosed Breast Cancer Patients Using PET/CT
  2. Kurdziel, K. A.; Kalen, J. D.; Hirsch, J. I.; Wilson, J. D.; Bear, H. D.; Logan, J.; McCumisky, J.; Moorman-Sykes, K.; Adler, S.; Choyke, P. L.
  3. Journal of Nuclear Medicine. 2011, Sep; 52(9): 1339-1345.
  1. 6.   Exploring the energy landscape of a molecular engineered analog of a tumor-homing peptide
  2. Revilla-Lopez, G.; Torras, J.; Nussinov, R.; Aleman, C.; Zanuy, D.
  3. Physical Chemistry Chemical Physics. 2011, Jun 7; 13(21): 9986-9994.
  1. 7.   Nanotechnology-Based Cancer Therapeutics-Promise and Challenge-Lessons Learned Through the NCI Alliance for Nanotechnology in Cancer
  2. Farrell, D.; Ptak, K.; Panaro, N. J.; Grodzinski, P.
  3. Pharmaceutical Research. 2011, Feb; 28(2): 273-278.
  1. 8.   The Assembly-Inducing Laulimalide/Peloruside A Binding Site on Tubulin: Molecular Modeling and Biochemical Studies with [H-3]Peloruside A
  2. Nguyen, T. L.; Xu, X. M.; Gussio, R.; Ghosh, A. K.; Hamel, E.
  3. Journal of Chemical Information and Modeling. 2010, Nov; 50(11): 2019-2028.
  1. 9.   Minireview: Nanoparticles and the Immune System
  2. Zolnik, B. S.; Gonzalez-Fernandez, A.; Sadrieh, N.; Dobrovolskaia, M. A.
  3. Endocrinology. 2010, Feb; 151(2): 458-465.
  1. 10.   Biological Assessment of Triazine Dendrimer: Toxicological Profiles, Solution Behavior, Biodistribution, Drug Release and Efficacy in a PEGylated, Paclitaxel Construct
  2. Lo, S. T.; Stern, S.; Clogston, J. D.; Zheng, J. W.; Adiseshaiah, P. P.; Dobrovolskaia, M.; Lim, J. D.; Patri, A. K.; Sun, X. K.; Simanek, E. E.
  3. Molecular Pharmaceutics. 2010, Jul-Aug; 7(4): 993-1006.
  1. 11.   Survivin Is Not Induced by Novel Taxanes
  2. Sharifi, N.; Qi, J.; Bane, S.; Sharma, S.; Li, R.; Robey, R.; Figg, W. D.; Farrar, W. L.; Kingston, D. G. I.
  3. Molecular Pharmaceutics. 2010, Nov-Dec; 7(6): 2216-2223.
  1. 12.   A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors
  2. Azad, N.; Perroy, A.; Gardner, E.; Imamura, C. K.; Graves, C.; Sarosy, G. A.; Minasian, L.; Kotz, H.; Raggio, M.; Figg, W. D.; Kohn, E. C.
  3. Cancer Biology & Therapy. 2009 8(19): 1800-1805.
  1. 13.   Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment
  2. Gardner, E. R.; Dahut, W.; Figg, W. D.
  3. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences. 2008 862(1-2): 213-218.
  1. 14.   Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel
  2. Gardner, E. R.; Dahut, W. L.; Scripture, C. D.; Jones, J.; Aragon-Ching, J. B.; Desai, N.; Hawkins, M. J.; Sparreboom, A.; Figg, W. D.
  3. Clinical Cancer Research. 2008 14(13): 4200-4205.
  1. 15.   Design and synthesis of paclitaxel conjugated with an ErbB2-Recognizing pepticle, EC-1
  2. Li, P.; Jiang, S.; Pero, S. C.; Oligino, L.; Krag, D. N.; Michejda, C. J.; Roller, P. P.
  3. Biopolymers. 2007, Nov; 87(4): 225-230.
  1. 16.   In vitro efficacy of immuno-chemotherapy with anti-EGFR human fab-taxol conjugate on A431 epidermoid carcinoma cells
  2. Wang, X.; Zhu, J.; Zhao, P.; Jiao, Y. G.; Xu, N.; Grabinski, T.; Liu, C.; Miranti, C. K.; Fu, T.; Cao, B. B.
  3. Cancer Biology & Therapy. 2007, Jun; 6(6): 980-986.
  1. 17.   Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer
  2. Jimeno, A.; Hallur, G.; Chan, A.; Zhang, X. F.; Cusatis, G.; Chan, F.; Shah, P.; Chen, R. B.; Hamel, E.; Garrett-Mayer, E.; Khan, S.; Hidalgo, M.
  3. Molecular Cancer Therapeutics. 2007, May; 6(5): 1509-1516.
  1. 18.   Taxoids: Cancer-fighting compounds from nature
  2. Kingston, D. G. I.; Newman, D. J.
  3. Current Opinion in Drug Discovery & Development. 2007, Mar; 10(2): 130-144.
  1. 19.   Synergistic effects of peloruside a and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly
  2. Hamel, E.; Day, B. W.; Miller, J. H.; Jung, M. K.; Northcote, P. T.; Ghosh, A. K.; Curran, D. P.; Cushman, M.; Nicolaou, K. C.; Paterson, I.; Sorensen, E. J.
  3. Molecular Pharmacology. 2006, Nov; 70(5): 1555-1564.
  1. 20.   Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin
  2. Madiraju, C.; Edler, M. C.; Hamel, E.; Raccor, B. S.; Balachandran, R.; Zhu, G. Y.; Giuliano, K. A.; Vogt, A.; Shin, Y. S.; Fournier, J. H.; Fukui, Y. H.; Bruckner, A. M.; Curran, D. P.; Day, B. W.
  3. Biochemistry. 2005, NOV 15; 44(45): 15053-15063.
  1. 21.   Synthesis and biological evaluation of (-)-16-normethyldictyostatin: A potent analogue of (-)-dictyostatin
  2. Shin, Y.; Fournier, J. H.; Balachandran, R.; Madiraju, C.; Raccor, B. S.; Zhu, G.; Edler, M. C.; Hamel, E.; Day, B. W.; Curran, D. P.
  3. Organic Letters. 2005, JUL 7; 7(14): 2873-2876.
  1. 22.   The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase
  2. Marcus, A. I.; Zhou, J.; O'Brate, A.; Hamel, E.; Wong, J.; Nivens, N.; El-Naggar, A.; Yao, T. P.; Khuri, F. R.; Giannakakou, P.
  3. Cancer Research. 2005, MAY 1; 65(9): 3883-3893.
  1. 23.   Induction of stem cell factor/c-Kit/Slug signal transduction in multidrug-resistant malignant mesothelioma cells
  2. Catalano, A.; Rodilossi, S.; Rippo, M. R.; Caprari, P.; Procopio, A.
  3. Journal of Biological Chemistry. 2004, NOV 5; 279(45): 46706-46714.
  1. 24.   A quantitative evaluation of the effects of inhibitors of tubulin assembly on polymerization induced by discodermolide, epothilone B, and paclitaxel
  2. Dabydeen, D. A.; Florence, G. J.; Paterson, I.; Hamel, E.
  3. Cancer Chemotherapy and Pharmacology. 2004 53(5): 397-403.
  1. 25.   Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin
  2. Hamel, E.
  3. Cell Biochemistry and Biophysics. 2003 38(1): 1-21.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel